Akoya Biosciences, Inc. (AKYA)
Jul 8, 2025 - AKYA was delisted (reason: acquired by QTRX)
1.290
0.00 (0.00%)
Inactive · Last trade price on Jul 7, 2025

Akoya Biosciences Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
64114239363570-
Upgrade
Market Cap Growth
-69.95%-52.61%-34.07%-36.23%--
Upgrade
Enterprise Value
121159236347482-
Upgrade
Last Close Price
1.292.294.889.5715.31-
Upgrade
PS Ratio
0.801.392.484.8510.37-
Upgrade
PB Ratio
-14.944.456.204.69-
Upgrade
P/TBV Ratio
--13.2417.926.95-
Upgrade
EV/Sales Ratio
1.511.952.444.648.78-
Upgrade
Debt / Equity Ratio
-14.2211.081.591.290.271.94
Upgrade
Asset Turnover
0.600.540.540.410.410.51
Upgrade
Inventory Turnover
1.341.602.492.683.123.96
Upgrade
Quick Ratio
0.361.662.832.454.611.37
Upgrade
Current Ratio
0.612.613.453.035.091.67
Upgrade
Return on Equity (ROE)
-354.27%-180.45%-112.72%-78.52%-61.59%-63.92%
Upgrade
Return on Assets (ROA)
-17.49%-16.86%-19.65%-22.55%-17.33%-8.60%
Upgrade
Return on Capital (ROIC)
-23.89%-22.26%-25.58%-28.67%-22.44%-12.82%
Upgrade
Earnings Yield
-73.88%-48.78%-26.44%-19.45%-7.54%-
Upgrade
FCF Yield
-50.27%-41.02%-22.78%-16.75%-7.23%-
Upgrade
Buyback Yield / Dilution
-5.06%-11.22%-17.72%-40.34%-1034.62%-4.15%
Upgrade
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q